StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)

Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%

AbbVie Rinvoq (upadacitinib) by Quarter

Rinvoq (upadacitinib) — International operational (constant-currency) growth YoY (%) (%)

QuarterlyAnnual

AbbVie Rinvoq (upadacitinib): 29.2% in Q2 2026, down 8.3 pts from a year earlier. That is the lowest of the 15 quarters on record here.

Latest, Q2 2026
29.2%
Period ended Jun 30, 2026
Change on a year earlier
-8.3 pts
37.5% in Q2 2025
History
15 quarters
Since Q4 2022
Sources
15
Documents cited below

Where the Q2 2026 figure comes from

“|| Rinvoq | 1,765 | 760 | 2,525 | 21.6 | 31.9 | 24.5 | 29.2 | 23.7”

Source: Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗

Reported in Form 8-K Key Product Revenues Schedule.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedRinvoq (upadacitinib) — International operational (constant-currency) growth YoY (%) (%)Year on yearSource
Q2 2026Jun 30, 202629.2%-8.3 ptsForm 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗
Q1 2026Mar 31, 202632.6%-10.2 ptsForm 8-K (abbv-20260331xexhibit991.htm, filed 2026-04-29) ↗
Q4 2025Dec 31, 202533.2%-19.9 ptsForm 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Q3 2025Sep 30, 202536.5%-15.1 ptsForm 8-K (abbv-20250930xexhibit991.htm, filed 2025-10-31) ↗
Q2 2025Jun 30, 202537.5%-25.1 ptsForm 8-K (abbv-20250630xexhibit991.htm, filed 2025-07-31) ↗
Q1 2025Mar 31, 202542.8%-20.0 ptsForm 8-K (abbv-20250331xexhibit991.htm, filed 2025-04-25) ↗
Q4 2024Dec 31, 202453.1%-6.7 ptsForm 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗
Q3 2024Sep 30, 202451.6%-9.6 ptsForm 8-K (abbv-20240930xexhibit991.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 202462.6%+5.1 ptsForm 8-K (abbv-20240630xexhibit991.htm, filed 2024-07-25) ↗
Q1 2024Mar 31, 202462.8%-2.1 ptsForm 8-K (abbv-20240331xexhibit991.htm, filed 2024-04-26) ↗
Q4 2023Dec 31, 202359.8%-14.7 ptsForm 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗
Q3 2023Sep 30, 202361.2%–Form 8-K (abbv-20230930xexhibit991.htm, filed 2023-10-27) ↗
Q2 2023Jun 30, 202357.5%–Form 8-K (abbv-20230630xexhibit991.htm, filed 2023-07-27) ↗
Q1 2023Mar 31, 202364.9%–Form 8-K (abbv-20230331xexhibit991.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 202274.5%–Form 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗

Cite this data

StockData. (2026). AbbVie Rinvoq (upadacitinib) (%), quarterly Q4 2022–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/rinvoq-intl-op-yoy

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.